Fermenta Biotech Ltd
NSE: BSE: 506414
₹307.40
(0.34%)
Thu, 21 May 2026, 05:24 pm
Market Cap8.65B
PE Ratio10.24
Dividend0.85
Health Technology
Biotechnology
24.5KFermenta Biotech Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are thoroughly covered by earnings (76.6x coverage).
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- Fermenta Biotech's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Fermenta Biotech's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- Fermenta Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Fermenta Biotech is profitable, therefore cash runway is not a concern.
- Fermenta Biotech is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (31.4%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 1.5x debt.
- Fermenta Biotech's cash and other short term assets cover its long term commitments.
- Interest payments on debt are well covered by earnings (EBIT is 4.5x coverage).
- The level of debt compared to net worth has increased over the past 5 years (20.5% vs 69.8% today).
- Fermenta Biotech's level of debt (69.8%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Fermenta Biotech board of directors is about average.
- The tenure for the Fermenta Biotech management team is about average.
misc
- Fermenta Biotech is not covered by any analysts.
- Fermenta Biotech has significant price volatility in the past 3 months.
past
- Fermenta Biotech has delivered over 20% year on year earnings growth in the past 5 years.
- Fermenta Biotech used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Fermenta Biotech has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Fermenta Biotech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
- Fermenta Biotech's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Fermenta Biotech's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.
value
- Fermenta Biotech is good value based on earnings compared to the IN Pharmaceuticals industry average.
- Fermenta Biotech is good value based on earnings compared to the India market.
- 506414 outperformed the Market in India which returned -14.5% over the past year.
- BSE:506414 is up 23.8% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:506414 is up 23.8% outperforming the market in India which returned 8% over the past month.
- Fermenta Biotech's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Fermenta Biotech's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Fermenta Biotech is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- 506414 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Asset Management Companies
Popular Stocks
Indian Indices
Sector Wise Stocks
IPO
Share Market
Best MF Schemes
Platforms
Resources
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800